Sarepta Therapeutics Q4 Adj. EPS $(3.58) Misses $(1.31) Estimate, Sales $442.934M Beat $391.924M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsEarnings MissesNews
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.58) per share which missed the analyst consensus estimate of $(1.31) by 172.45 percent. This is a 288.42 percent decrease over earnings of $1.90 per
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(3.58) per share which missed the analyst consensus estimate of $(1.31) by 172.45 percent. This is a 288.42 percent decrease over earnings of $1.90 per share from the same period last year. The company reported quarterly sales of $442.934 million which beat the analyst consensus estimate of $391.924 million by 13.02 percent. This is a 32.73 percent decrease over sales of $658.412 million the same period last year.